Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Eton Pharmaceuticals and raises the price target from $8 to $10.
October 04, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Craig-Hallum has increased the price target for Eton Pharmaceuticals from $8 to $10, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in price target from $8 to $10 by Craig-Hallum, along with the maintained Buy rating, indicates a positive sentiment from the analyst. This is likely to boost investor confidence and potentially lead to a short-term increase in Eton Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100